These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21902287)

  • 1. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
    Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
    Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
    Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
    Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
    Johnson F; Setnik B
    Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
    Setnik B; Sommerville K; Goli V; Han L; Webster L
    Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
    Smith HS
    Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
    Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
    J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
    Katz N; Hale M; Morris D; Stauffer J
    Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
    Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
    Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
    J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.
    Setnik B; Goli V; Levy-Cooperman N; Mills C; Shram M; Smith I
    Pain Res Manag; 2013; 18(4):e55-62. PubMed ID: 23936895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users.
    Setnik B; Sommerville KW; Pixton GC; Webster L
    Curr Med Res Opin; 2019 Mar; 35(3):503-512. PubMed ID: 30293449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.